U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096882) titled 'SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection' on July 24.
Brief Summary: The goal of this clinical trial is to evaluate the safety profile and tolerability of SDT-M001 injection in NSCLC patients with driver-gene-negative and negative PD-L1 expression after radical surgical resection; to determine the recommended Phase II dose (RP2D).
Study Start Date: July 26
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Intervention:
BIOLOGICAL: SDT-M001 injection
Cascade primed immune cells(CAPRI); SDT-M001 injection is administered at three dose levels:1.5e9 cells, 3e9 cells,6...